Compound Evidence File
#EC-2026-0947
Dihexa
Filed under Oral Tablets. The bureau holds 158 laboratory returns for this compound from 57 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
57 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 4 | 10.0 | 9.9 | 10.0 | 21 May 2026 | 21 May 2026 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 4 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 4 | 10.0 | 9.9 | 10.0 | 2 Jan 2026 | 10 Jul 2026 |
| BachemCASE #VI-2026-0314 | A | 4 | 10.0 | 9.9 | 10.0 | 8 Jan 2026 | 14 May 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 4 | 10.0 | 9.9 | 10.0 | 1 Apr 2026 | 28 Jun 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 4 | 10.0 | 9.9 | 10.0 | 13 Feb 2026 | 3 Aug 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 4 | 10.0 | 9.9 | 10.0 | 11 Dec 2025 | 8 Aug 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 3 | 10.0 | 9.9 | 10.0 | 16 Dec 2025 | 21 Mar 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 3 | 10.0 | 9.9 | 10.0 | 9 May 2026 | 24 Jun 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 3 | 10.0 | 10.0 | 10.0 | 14 Feb 2026 | 8 Jul 2026 |
| SinoPepCASE #VI-2026-0387 | A | 3 | 10.0 | 9.9 | 10.0 | 23 Feb 2026 | 13 Aug 2026 |
| AsymchemCASE #VI-2026-0091 | A | 2 | 10.0 | 10.0 | 10.0 | 21 Jun 2026 | 10 Jul 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 2 | 10.0 | 10.0 | 10.0 | 11 Apr 2026 | 24 Apr 2026 |
| CellupepCASE #VI-2026-0888 | X | 1 | 10.0 | 10.0 | 10.0 | 16 Mar 2025 | 16 Mar 2025 |
| LSPLCASE #VI-2026-0523 | X | 1 | 10.0 | 10.0 | 10.0 | 27 Feb 2025 | 27 Feb 2025 |
| QYAOBIOCASE #VI-2026-0861 | A | 4 | 9.9 | 9.9 | 10.0 | 22 Nov 2025 | 23 Jun 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 4 | 9.9 | 9.9 | 10.0 | 19 Nov 2025 | 1 May 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 4 | 9.9 | 9.9 | 10.0 | 6 Jan 2026 | 25 May 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 4 | 9.9 | 9.9 | 10.0 | 10 Feb 2026 | 9 Jul 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 3 | 9.9 | 9.9 | 9.9 | 17 Dec 2025 | 8 May 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 3 | 9.9 | 9.9 | 9.9 | 12 Nov 2025 | 26 Jul 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 3 | 9.9 | 9.9 | 10.0 | 16 Feb 2026 | 10 Aug 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 2 | 9.9 | 9.9 | 10.0 | 23 Mar 2026 | 26 Jun 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 2 | 9.9 | 9.9 | 10.0 | 6 Dec 2025 | 4 Apr 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 2 | 9.9 | 9.9 | 9.9 | 14 May 2026 | 18 Aug 2026 |
| Risynth BioCASE #VI-2026-0672 | X | 1 | 9.9 | 9.9 | 9.9 | 17 Dec 2024 | 17 Dec 2024 |
| Haikou Mingheng TechnologyCASE #VI-2026-0250 | X | 1 | 9.8 | 9.8 | 9.8 | 27 Feb 2025 | 27 Feb 2025 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 7 | 8.6 | 7.6 | 9.5 | 24 May 2026 | 24 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 6 | 8.5 | 7.9 | 9.1 | 24 May 2026 | 24 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 2 | 8.4 | 8.4 | 8.4 | 24 May 2026 | 24 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 5 | 8.3 | 7.8 | 9.3 | 24 May 2026 | 24 May 2026 |
| Lux Synth AminosCASE #VI-2026-0700 | X | 1 | 8.3 | 8.3 | 8.3 | 9 Jun 2025 | 9 Jun 2025 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 4 | 8.0 | 6.1 | 9.9 | 24 May 2026 | 24 May 2026 |
| ZZQ PeptidesCASE #VI-2026-0550 | X | 1 | 7.8 | 7.8 | 7.8 | 13 Feb 2025 | 13 Feb 2025 |
| LN PeptidesCASE #VI-2026-0781 | X | 2 | 7.7 | 6.5 | 8.9 | 25 Apr 2025 | 17 May 2026 |
| Prime PeptidesCASE #VI-2026-0696 | X | 1 | 7.7 | 7.7 | 7.7 | 13 Jun 2025 | 13 Jun 2025 |
| ZLZ PeptideCASE #VI-2026-0524 | X | 7 | 7.5 | 5.2 | 9.4 | 28 Mar 2025 | 21 May 2026 |
| Haikou Mingheng BiotechnologyCASE #VI-2026-0126 | X | 1 | 6.9 | 6.9 | 6.9 | 17 Dec 2024 | 17 Dec 2024 |
| Eros PeptidesCASE #VI-2026-0918 | X | 1 | 6.9 | 6.9 | 6.9 | 28 Mar 2025 | 28 Mar 2025 |
| UtherCASE #VI-2026-0902 | X | 4 | 6.8 | 5.2 | 8.2 | 20 Jun 2025 | 23 May 2026 |
| Top PeptideCASE #VI-2026-0721 | X | 1 | 6.8 | 6.8 | 6.8 | 28 Mar 2025 | 28 Mar 2025 |
| Shandong Nuoweiou Medical Technology CoCASE #VI-2026-0076 | X | 1 | 6.7 | 6.7 | 6.7 | 16 Mar 2025 | 16 Mar 2025 |
| Biolongevity LabsCASE #VI-2026-0442 | X | 1 | 6.7 | 6.7 | 6.7 | 13 Jun 2025 | 13 Jun 2025 |
| SRY LabsCASE #VI-2026-0657 | X | 11 | 6.6 | 3.7 | 8.4 | 13 Jun 2025 | 20 May 2026 |
| TSC Top Supplements ChinaCASE #VI-2026-0523 | X | 8 | 6.5 | 4.4 | 10.0 | 8 Jul 2025 | 25 May 2026 |
| Verified PeptidesCASE #VI-2026-0407 | X | 2 | 6.5 | 6.1 | 6.9 | 11 Jun 2025 | 23 May 2026 |
| Hunan GoodPeptides Biotech CoCASE #VI-2026-0370 | X | 1 | 6.5 | 6.5 | 6.5 | 17 Dec 2024 | 17 Dec 2024 |
| NextGen HealthCASE #VI-2026-0604 | X | 1 | 6.4 | 6.4 | 6.4 | 11 Jun 2025 | 11 Jun 2025 |
| Zen PeptidesCASE #VI-2026-0940 | X | 1 | 6.3 | 6.3 | 6.3 | 3 Jul 2025 | 3 Jul 2025 |
| Bio PepzCASE #VI-2026-0436 | X | 1 | 6.2 | 6.2 | 6.2 | 11 Jun 2025 | 11 Jun 2025 |
| Xingtai Pukelai Technology CoCASE #VI-2026-0850 | X | 1 | 6.1 | 6.1 | 6.1 | 13 Jun 2025 | 13 Jun 2025 |
| Yongkang Nuoao Trading CoCASE #VI-2026-0646 | X | 1 | 5.8 | 5.8 | 5.8 | 2 Apr 2025 | 2 Apr 2025 |
| HXNetCASE #VI-2026-0061 | X | 3 | 5.4 | 3.8 | 6.6 | 16 Mar 2025 | 20 May 2026 |
| Amplified AminoCASE #VI-2026-0748 | X | 1 | 3.8 | 3.8 | 3.8 | 28 Mar 2025 | 28 Mar 2025 |
| Amino AmigosCASE #VI-2026-0061 | X | 1 | 3.1 | 3.1 | 3.1 | 16 Mar 2025 | 16 Mar 2025 |
| Advanced Technology and IndustrialCASE #VI-2026-0133 | X | 1 | 0.6 | 0.6 | 0.6 | 9 Jun 2025 | 9 Jun 2025 |
| Explicit SarmsCASE #VI-2026-0017 | X | 1 | 0.0 | 0.0 | 0.0 | 20 Jun 2025 | 20 Jun 2025 |
Open any subject to view the batch-level evidence for Dihexa alone.